Language
English
Publication Date
8-1-2024
Journal
Pediatric Blood & Cancer
DOI
10.1002/pbc.31061
PMID
38840429
PMCID
PMC11648260
PubMedCentral® Posted Date
12-16-2024
PubMedCentral® Full Text Version
Author MSS
Abstract
Chronic hemolytic anemia and vascular occlusion are hallmarks of sickle cell disease (SCD). Blood transfusions are critical for supportive and preventive management of SCD complications. Patients with SCD are at risk for hyperhemolysis syndrome (HHS), a subtype of delayed hemolytic transfusion reactions. HHS management includes intravenous immunoglobulin, corticosteroids, and avoidance of further transfusions. Not all patients respond to first-line agents. Eculizumab, which blocks terminal complement activation, has been proposed as second-line management of HHS. We describe two patients who received eculizumab for refractory HHS. In our experience, eculizumab is a safe and effective option for refractory pediatric HHS.
Keywords
Humans, Antibodies, Monoclonal, Humanized, Anemia, Sickle Cell, Male, Female, Child, Hemolysis, Adolescent, Child, Preschool, Transfusion Reaction, delayed hemolytic transfusion reactions, eculizumab, hyperhemolysis syndrome, sickle cell disease
Published Open-Access
yes
Recommended Citation
Ajibike Lapite, Saleh Bhar, and Titilope Fasipe, "Eculizumab for Management of Hyperhemolysis Syndrome in Pediatric Patients With Sickle Cell Disease: A Single-Center Case Series" (2024). Faculty and Staff Publications. 3054.
https://digitalcommons.library.tmc.edu/baylor_docs/3054
Included in
Critical Care Commons, Hematology Commons, Hemic and Lymphatic Diseases Commons, Medical Sciences Commons, Pediatrics Commons